Vitamin D Council needs your help...

Tax-deductible!

Together we can end the illness and disease caused by the worldwide epidemic of vitamin D deficiency.

About Vitamin D Council

Contact Vitamin D Council

Sponsor Vitamin D Council

Follow us on:

Vitamin D Products

(off-site)

These companies donate to the Vitamin D Council.

D-Lite, Renew, & SunSplash UV/Tanning Systems
In-Home ZRT Vitamin D Blood Test Kit
Get Premium Quality Vitamin D Supplements at Great Prices
Vitamin D3 Plus™ from Bio-Tech — contains the cofactors Vitamin D needs to work properly.

Vitamin D Research

back to research menu

Renal Function

The impact of diabetes mellitus on vitamin D metabolism in predialysis patients. Bone. 2009 Nov;45(5):949–55.
Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis. 2009 Oct;54(4):647–52.
Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Clin Immunol. 2009 Oct;133(1):69–77.
Characterization of acute renal allograft rejection by human serum proteomic analysis. J Huazhong Univ Sci Technolog Med Sci. 2009 Oct;29(5):585–91.
Parathyroid Hormone as a Mortality Predictor in Frail Aged Inpatients. Gerontology. 2009 Sep 15.
Hypergravity modulates vitamin D receptor target gene mRNA expression in mice. Am J Physiol Endocrinol Metab. 2009 Sep;297(3):E728–34.
Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Renal Physiol. 2009 Sep;297(3):F791–801.
The full-length calcium-sensing receptor dampens the calcemic response to 1alpha,25(OH)2 vitamin D3 in vivo independently of parathyroid hormone. Am J Physiol Renal Physiol. 2009 Sep;297(3):F720–8.
Expression of 25-hydroxyvitamin D-1alpha-hydroxylase (1alphaOHase, CYP27B1) splice variants in HaCaT keratinocytes and other skin cells: modulation by culture conditions and UV-B treatment in vitro. Anticancer Res. 2009 Sep;29(9):3659–67.
Vitamin D status, bone mineral density, and inflammation in kidney transplantation patients. Transplant Proc. 2009 Sep;41(7):2823–5.
Successful treatment of postsurgical hypoparathyroidism by intramuscular injection of vitamin D(3) in a patient associated with malabsorption syndrome due to multiple abdominal surgeries. J Bone Miner Metab. 2009 Aug 6.
Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats. Nephrol Dial Transplant. 2009 Aug;24(8):2354–61.
Potential of alfacalcidol for reducing increased risk of falls and fractures. Rheumatol Int. 2009 Aug;29(10):1177–85.
Vitamin D Receptor (VDR) Gene Polymorphism is Associated with Left Ventricular (LV) Mass and Predicts LVH Progression in End Stage Renal Disease (ESRD) Patients. J Bone Miner Res. 2009 Jul 20.
Calcium malabsorption does not cause secondary hyperparathyroidism. Calcif Tissue Int. 2009 Jul;85(1):31–6.
FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009 Jul;94(7):2332–7.
Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men. Osteoporos Int. 2009 Jul;20(7):1167–73.
Vitamin D insufficiency and deficiency in children with early chronic kidney disease. J Pediatr. 2009 Jun;154(6):906–11.e1.
The same annual dose of 292 000 IU of vitamin D(3) (cholecalciferol) on either daily or four monthly basis for elderly women: 1-year comparative study of the effects on serum 25(OH)D(3) concentrations and renal function. Clin Endocrinol (Oxf). 2009 May 25.
A new axis of phosphate balance control: Fibroblast Growth Factor 23-Klotho. Nephrol Ther. 2009 May 21.
Achieving chronic kidney disease treatment targets in renal transplant recipients: results from a cross-sectional study in Spain. Transplantation. 2009 May 15;87(9):1340–6.
Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol. 2009 May;20(5):955–60.
Acute kidney injury due to anabolic steroid and vitamin supplement abuse: report of two cases and a literature review. Int Urol Nephrol. 2009 Apr 23.
Bone mineral density and secondary hyperparathyroidism in pulmonary hypertension. Open Respir Med J. 2009 Apr 14;3:53–60.
Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient. Am J Med Sci. 2009 Apr;337(4):300–1.
Effects of receptor-mediated endocytosis and tubular protein composition on volume retention in experimental glomerulonephritis. Am J Physiol Renal Physiol. 2009 Apr;296(4):F902–11.
Vitamin D metabolism impairment in the rat's offspring following maternal exposure to 137cesium. Arch Toxicol. 2009 Apr;83(4):357–62.
Chronic kidney disease (CKD) and bone. Chronic kidney disease—mineral and bone disorder in predialysis patients. Clin Calcium. 2009 Apr;19(4):493–9.
Intestinal vitamin D receptor is required for normal calcium and bone metabolism in mice. Gastroenterology. 2009 Apr;136(4):1317–27, e1–2.
Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients. Bone. 2009 Apr;44(4):678–83.
Calcium and Phosphorus Homeostasis. Blood Purif. 2009 Mar 23;27(4):387–394.
Oncogenic osteomalacia from pterygopalatine fossa mass. J Laryngol Otol. 2009 Mar 2:1–3.
Vitamin D metabolism and vitamin D traditional and nontraditional, target organs: implications for kidney patients. J Ren Care. 2009 Mar;35 Suppl 1:39–44.
The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD. Am J Kidney Dis. 2009 Mar;53(3):408–16.
Calcium metabolism in the early posttransplantation period. Clin J Am Soc Nephrol. 2009 Mar;4(3):665–72.
Absence of adynamic bone disease in African- Americans with CKD Stage 5 after 3 years of vitamin D therapy guided by iPTH and the PTH-(1-84)/N-terminally truncated PTH fragments ratio. Clin Nephrol. 2009 Mar;71(3):267–75.
Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift? Nat Clin Pract Nephrol. 2009 Jan;5(1):24–33.
Association of Serum Intact Parathyroid Hormone with Lower Estimated Glomerular Filtration Rate. Clin J Am Soc Nephrol. 2009 Jan;4(1):186–94.
Rheumatic manifestations of renal disease. Curr Opin Rheumatol. 2009 Jan;21(1):55–61. Review.
Vitamin D and the vasculature: can we teach an old drug new tricks? Expert Opin Ther Targets. 2009 Jan;13(1):29–38.
Analysis of CYP27B1, encoding 25-hydroxyvitamin D-1alpha-hydroxylase, as a candidate tumor suppressor gene in primary and severe secondary/tertiary hyperparathyroidism. J Bone Miner Res. 2009 Jan;24(1):102–4.
The vitamin D deficiency pandemic and consequences for nonskeletal health: Mechanisms of action. Mol Aspects Med. 2008 Dec;29(6):361–8. Review.
A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet. Eur J Endocrinol. 2008 Dec;159 Suppl 1:S101–5.
Loss of vitamin d receptor produces polyuria by increasing thirst. J Am Soc Nephrol. 2008 Dec;19(12):2396–405.
Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant. 2008 Nov;23(11):3670–6.
Role of bone biopsy in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol. 2008 Nov;3 Suppl 3:S170–4.
Vitamin D deficiency in children with renal disease. Arch Dis Child. 2008 Nov;93(11):959–62.
Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535–41.
Prospective study of combined treatment with interferon-alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma. Int J Urol. 2008 Sep;15(9):794–9.
Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol. 2008 Aug;19(8):1509–19.
African Americans, 25-hydroxyvitamin D, and osteoporosis: a paradox. Am J Clin Nutr. 2008 Aug;88(2):545S–550S. Review.
Vitamin D across the lifecycle: physiology and biomarkers. Am J Clin Nutr. 2008 Aug;88(2):500S–506S. Review.
Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients. Chin Med J (Engl). 2008 Jul 20;121(14):1280–4.
Mineral metabolism and bone abnormalities in children with chronic renal failure. Rev Endocr Metab Disord. 2008 Jun;9(2):131–7. Review.
Enriched uranium affects the expression of vitamin D receptor and retinoid X receptor in rat kidney. J Steroid Biochem Mol Biol. 2008 Jun;110(3–5):263–8.
Insulin resistance, renal injury, renal 1-alpha hydroxylase, and bone homeostasis in aged obese rats. Arch Med Res. 2008 May;39(4):380–7.
Long-term outcome after parathyroidectomy in patients with advanced primary hyperparathyroidism and associated vitamin D deficiency. World J Surg. 2008 May;32(5):829–35.
Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract. 2008 Jan–Feb;14(1):10–7.
Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis). Nefrologia. 2008;28 Suppl 3:67–78. In Spanish.
Vitamin D and its implications for musculoskeletal health in women: An update. Maturitas. 2007 Oct 20;58(2):117–37. Review.
25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2007 Jul;50(1):69–77.
Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis. 2007 Jul;50(1):59–68.
Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3). Semin Dial. 2007 Jul;20(4):316–324.
Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int. 2007 Jul;11(3):315–21.
25-Hydroxyvitamin D Levels and Albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). AJKD. Volume 50, Issue 1, Pages 69–77 (July 2007).
Effect of 2-Methylene-19-nor-(20S)-1alpha-Hydroxy- Bishomopregnacalciferol (2MbisP), an Analog of Vitamin D, on Secondary Hyperparathyroidism. J Bone Miner Res. 2007 May;22(5):686–94.
Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):134–44. Review.
In vivo effects of chronic contamination with depleted uranium on vitamin D(3) metabolism in rat. Biochim Biophys Acta. 2007 Feb;1770(2):266–72.
Vitamin D and vascular calcification. Curr Opin Lipidol. 2007 Feb;18(1):41–6.
25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int. 2007 Jan;71(2):134–9.
Nutritional vitamin D deficiency presenting as hemichorea. J Child Neurol. 2007 Jan;22(1):74–6.
Osteomalacia and secondary hyperparathyroidism after kidney transplantation: Relationship to vitamin D deficiency. Am J Med Sci. 2007 Jan;333(1):58–62.
Cross-sectional analysis of abnormalities of mineral homeostasis, vitamin D and parathyroid hormone in a cohort of pre-dialysis patients. The chronic renal impairment in Birmingham (CRIB) study. Nephron Clin Pract. 2007;107(3):c109–16.
Effects of parathyroidectomy on bone remodeling markers and vitamin D status in patients with chronic kidney disease-mineral and bone disorder. Int Urol Nephrol. 2007;39(4):1251–6.
Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007;27(1):36–43.
Severe vitamin D deficiency in chronic renal failure patients on peritoneal dialysis. Clin Nephrol. 2006 Oct;66(4):247–55.
Renal tubular acidosis type 2 with Fanconi's syndrome, osteomalacia, osteoporosis, and secondary hyperaldosteronism in an adult consequent to vitamin D and calcium deficiency: effect of vitamin D and calcium citrate therapy. Endocr Pract. 2006 Sep–Oct;12(5):559–67.
Chronic contamination with 137Cesium affects Vitamin D3 metabolism in rats. Toxicology. 2006 Aug 1;225(1):75–80.
Effects of depleted uranium after short-term exposure on vitamin D metabolism in rat. Arch Toxicol. 2006 Aug;80(8):473–480.
Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J Pharmacol Exp Ther. 2006 Jul;318(1):90–8.
Osteoporotic fractures and vitamin D deficiency. Aust Fam Physician. 2006 Jul;35(7):519–20, 522.
Short-term hepatic effects of depleted uranium on xenobiotic and bile acid metabolizing cytochrome P450 enzymes in the rat. Arch Toxicol. 2006 Apr;80(4):187–95.
Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia J Clin Invest. 116:1703–1712 (2006) March.
Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 2006 Jan;69(1):33–43. Review.
Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int. 2005 Nov;68(5):1973–81. Review.
25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int. 2005 Oct;68(4):1840–8.
The role of vitamin D in vascular calcification in chronic kidney disease. Semin Dial. 2005 Jul–Aug;18(4):307–14. Review.
Vitamin D for health and in chronic kidney disease. Semin Dial. 2005 Jul–Aug;18(4):266–75. Review.
Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis. 2005 Jun;45(6):1026–33.
Alternative splicing of vitamin D-24-hydroxylase: a novel mechanism for the regulation of extrarenal 1,25-dihydroxyvitamin D synthesis. J Biol Chem. 2005 May 27;280(21):20604–11.
Vitamin-D receptor (VDR) gene (Fok-I, Taq-I and Apa-I) polymorphisms in healthy individuals from north Indian population. Asian Pac J Cancer Prev. 2005 Apr–Jun;6(2):147–52.
Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol. 2004 Sep–Oct;24(5):503–10.
High ratio of 1,25-dihydroxyvitamin D3 to parathyroid hormone in serum of tuberculous patients with end-stage renal disease. Clin Nephrol. 2004 Sep;62(3):202–7.
1alpha,25-dihydroxyvitamin D3 inducible transcription factor and its role in the vitamin D action. Endocr Regul. 2004 Mar;38(1):29–38. Review.
Serum levels of prostate-specific antigen and vitamin D in peritoneal dialysis patients. Adv Perit Dial. 2004;20:203–8.
Altered gene expression profile in the kidney of vitamin D receptor knockout mice. J Cell Biochem. 2003 Jul 1;89(4):709–19.
The immunological functions of the vitamin D endocrine system. Cell Mol Biol (Noisy-le-grand). 2003 Mar;49(2):277–300. Review.
Renal failure and vitamin D. Clin Calcium. 2002 Jun;12(6):711–23. In Japanese.
Cytochrome P450 enzymes in the bioactivation of vitamin D to its hormonal form (review). Int J Mol Med. 2001 Feb;7(2):201–9. Review.
Human 25-hydroxyvitamin D-1alpha-hydroxylase: cloning, mutations, and gene expression. Pediatr Nephrol. 2000 Jul;14(7):620–5. Review.
24,25-dihydroxyvitamin D3 in combination with 1,25-dihydroxyvitamin D3 ameliorates renal osteodystrophy in rats with chronic renal failure. Clin Nephrol. 2000 May;53(5):362–71.
Regulation of renal calbindin-D28K. Pharmacol Toxicol. 2000;87 Suppl 3:5–30. Review.
Liver granulomatosis is not an exceptional cause of hypercalcemia with hypoparathyroidism in dialysis patients. J Nephrol. 1999 Nov–Dec;12(6):398–403.
Genetic mutation in the human 25-hydroxyvitamin D3 1alpha-hydroxylase gene causes vitamin D-dependent rickets type I. Mol Cell Endocrinol. 1999 Oct 25;156(1–2):7–12. Review.
Genetic causes of rickets. Curr Opin Pediatr. 1999 Aug;11(4):333–9. Review.
Vitamin D analogs: perspectives for treatment. Miner Electrolyte Metab. 1999 Jul–Dec;25(4–6):337–41. Review.
The renal function of 25-hydroxyvitamin D3-1alpha-hydroxylase. Mol Cell Endocrinol. 1999 May 25;151(1–2):213–20. Review.
The 25-hydroxyvitamin D 1-alpha-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J Bone Miner Res. 1997 Oct;12(10):1552–9.
Saccharated ferric oxide (SFO)-induced osteomalacia: in vitro inhibition by SFO of bone formation and 1,25-dihydroxy-vitamin D production in renal tubules. Bone. 1997 Jul;21(1):57–64.
Vitamin D3 analogs and salmon calcitonin partially reverse the development of renal osteodystrophy in rats. Calcif Tissue Int. 1995 Nov;57(5):385–91.
24,25-dihydroxy vitamin D3 treatment inhibits parathyroid-stimulated adenylate cyclase in iliac crest biopsies from uremic patients. Bone. 1993 Mar-Apr;14(2):125–31.
Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3. Miner Electrolyte Metab. 1993;19(2):78–85.
Determinants of intact parathyroid hormone and free 1,25-dihydroxyvitamin D levels in mild and moderate renal failure. Nephron. 1992;61(4):422–7.
Lack of relationship between parathyroid hormone and 1,25-dihydroxyvitamin D in chronic renal failure. Nephron. 1991;58(2):144–9.
Effect of single oral phosphate loading on vitamin D metabolites in normal subjects and in X-linked hypophosphatemic rickets. Bone Miner. 1989 Sep;7(2):159–69.
Reduced deposition of aluminium in trabecular bone of uraemic rats treated with dihydroxylated vitamin D metabolites. Nephrol Dial Transplant. 1989;4(11):957–65.
Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab. 1988 Nov;67(5):876–81.
Effects of 1 alpha,25- and 24R,25-dihydroxyvitamin D3 on aluminum-induced rickets in growing uremic rats. J Bone Miner Res. 1987 Dec;2(6):533–45.
Influence of cadmium on the metabolism of vitamin D3 in rats. Toxicol Appl Pharmacol. 1987 Jun 30;89(2):158–64.
Main endocrine modulators of vitamin D hydroxylases in human pathophysiology. J Steroid Biochem. 1987;27(4–6):815–24. Review.
Metabolism of vitamin D in patients with primary biliary cirrhosis and alcoholic liver disease. Clin Sci (Lond). 1985 Nov;69(5):561–70.
Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest. 1984 Jun;73(6):1580–9.
Vitamin D metabolism and chronic liver disease. Ann Clin Lab Sci. 1984 May–Jun;14(3):189–97. Review.
Measurement of vitamin D metabolites in anephric subjects. Nephron. 1984;36(4):230–4.
Determinants of serum 1,25(OH)2D levels in renal disease. Kidney Int. 1983 Jul;24(1):104–9.
Impaired phosphorus conservation and 1,25 dihydroxyvitamin D generation during phosphorus deprivation in familial hypophosphatemic rickets. J Clin Invest. 1983 Jun;71(6):1562–9.
Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency. Kidney Int. 1982 Apr;21(4):627–32.
Vitamin D metabolism in hypoparathyroidism. J Clin Endocrinol Metab. 1980 Sep;51(3):606–10.
Recent advances on vitamin D. Diabete Metab. 1980 Jun;6(2):159–68. Review.
Rickets in adult cystic fibrosis with myopathy, pancreatic insufficiency and proximal renal tubular dysfunction. Am J Med. 1977 Sep;63(3):488–92.
Advances in vitamin D metabolism as they pertain to chronic renal disease. Am J Clin Nutr. 1976 Nov;29(11):1283–99.
Vitamin D: the discovery of its metabolites and their therapeutic applications. Pediatrics. 1976 May;57(5):729–41. Review.
Osteoporosis and osteomalacia. Schweiz Med Wochenschr. 1975 Apr 12;105(15):466–70.
The kidney as an endocrine organ involved in the function of vitamin D. Am J Med. 1975 Jan;58(1):39–47. Review.
The role of the kidney and vitamin D metabolism in health and disease. Clin Orthop Relat Res. 1974 Jan–Feb;(98):258–87.
The kidney as an endocrine organ for the production of 1,25-dihydroxyvitamin D 3 , a calcium-mobilizing hormone. N Engl J Med. 1973 Aug 16;289(7):359–65. Review.
Vitamin D metabolism and chronic kidney insufficiency. Dtsch Med Wochenschr. 1973 Jul 6;98(27):1338–44. Review in German.
The metabolic fate of vitamin D3-3H in chronic renal failure. J Clin Invest. 1968 October; 47(10): 2239–2252.

back to research menu

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Unless otherwise expressly stated, all site content licensed under a Creative Commons License.